Related Experiment Videos

[Global therapy of diabetic dyslipidemia: benefits and new therapeutic approaches]

Rafael Carmena1, Juan F Ascaso

  • 1Servicio de Endocrinología y Nutrición, Departamento de Medicina, Hospital Clínico Universitario, Universidad de Valencia, Valencia, España. carmena@uv.es

Medicina Clinica
|January 5, 2010
PubMed

Insights

Diabetic dyslipidemia management requires combining statins with agents targeting triglycerides and HDL cholesterol to reduce residual cardiovascular risk in type 2 diabetes patients. Future treatments will likely involve combination therapies for optimal lipid control.

Area of Science:

  • Cardiology
  • Endocrinology
  • Metabolic Syndrome

Context:

  • Diabetic dyslipidemia, a lipid triad of high triglycerides, low HDL, and dense LDL, significantly increases cardiovascular risk in type 2 diabetes.
  • Statin monotherapy reduces cardiovascular events but leaves residual risk due to incomplete dyslipidemia control.

Purpose:

  • To review the global therapeutic approach for diabetic dyslipidemia.
  • To highlight the necessity of combining statins with agents that effectively lower triglycerides and raise HDL cholesterol, even when LDL is at target.

Summary:

  • Combination therapy, including statins with other lipid-lowering agents, can normalize lipid profiles and potentially reduce cardiovascular risk.
  • The review discusses current data supporting combination therapies and ongoing clinical trials evaluating their impact on cardiovascular outcomes.

Impact:

  • Suggests that future treatments for diabetic dyslipidemia will involve combination therapies for improved cardiovascular risk management.
  • Emphasizes the need for a comprehensive approach beyond statin monotherapy to address the complex lipid abnormalities in diabetic patients.

Related Concept Videos

Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...